SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Opko Health, Inc. – ‘8-K’ for 1/23/13 – EX-99.1

On:  Tuesday, 1/29/13, at 5:22pm ET   ·   For:  1/23/13   ·   Accession #:  1193125-13-28347   ·   File #:  1-33528

Previous ‘8-K’:  ‘8-K’ on 1/9/13 for 1/8/13   ·   Next:  ‘8-K’ on 2/5/13 for 1/30/13   ·   Latest:  ‘8-K’ on / for 5/7/24   ·   1 Reference:  By:  Opko Health, Inc. – ‘10-K’ on 2/18/21 for 12/31/20

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 1/29/13  Opko Health, Inc.                 8-K:1,2,3,8 1/23/13    4:331K                                   RR Donnelley/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     30K 
 2: EX-10.1     Form of Note Purchase Agreement                     HTML    300K 
 3: EX-99.1     Press Release                                       HTML      7K 
 4: EX-99.2     Press Release                                       HTML     10K 


EX-99.1   —   Press Release


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  PRESS RELEASE  

Exhibit 99.1

 

LOGO

OPKO ANNOUNCES PROPOSED PRIVATE OFFERING OF

$150 MILLION CONVERTIBLE SENIOR NOTES DUE 2033

MIAMIJanuary 23, 2013—OPKO Health, Inc. (NYSE: OPK) announced today that it plans to sell approximately $150 million aggregate principal amount of convertible senior notes due 2033 (the “Notes”) in a private offering. The Notes will be OPKO’s senior unsecured obligations and will rank equally with all of OPKO’s other existing and future senior unsecured debt. The interest rate, conversion rate and other terms of the Notes will be determined at the time of pricing of the offering. The planned offering of Notes is subject to market conditions and other factors and no assurance can be given that the offering will be completed.

OPKO intends to use the net proceeds from this offering for general corporate purposes, including research and development expenses, acceleration of clinical trials, acquisitions of new technologies or businesses and other business opportunities.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes and the shares of OPKO common stock issuable upon conversion of the Notes will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from registration requirements.

OPKO Health, Inc.

Steven D. Rubin or Juan F. Rodriguez 305-575-4100


Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on:1/29/13None on these Dates
For Period End:1/23/13
 List all Filings 


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/18/21  Opko Health, Inc.                 10-K       12/31/20  111:16M
Top
Filing Submission 0001193125-13-028347   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 9, 12:46:08.1am ET